Thioredoxin reductase as a novel molecular target for cancer therapy

Cancer Letters

Volumn 236, Issue 2, 2006, Pages 164-174

  Nguyen, Phuongmai ^a   Awwad, Rania T ^a   Smart, Dee Dee K ^a   Spitz, Douglas R ^b   Gius, David ^a  

^a Radiation Research Program   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Anticancer agents; Molecular targets; Thioredoxin reductase

Indexed keywords

ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFIDE; THIOREDOXIN; THIOREDOXIN REDUCTASE; ENZYME INHIBITOR; FREE RADICAL; THIOREDOXIN REDUCTASE 1;

APOPTOSIS; CELL ACTIVATION; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; GENE TARGETING; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR CELL; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; REVIEW; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FREE RADICALS; HUMANS; NEOPLASMS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; THIOREDOXIN; THIOREDOXIN REDUCTASE (NADPH);

EID: 33746430147     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.04.028     Document Type: Review

References (91)

1. Halliwell B., and Gutteridge J.M. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 186 (1990) 1-85
2. Hill C.S., and Treisman R. Transcriptional regulation by extracellular agents: mechanisms and specificity. Cell 80 (1995) 199-211
3. Curry H.A., Clemens R.A., Shah S., Bradbury C.M., Botero A., Goswami P., and Gius D. Heat shock inhibits radiation-induced activation of NF-κB via inhibition of I-κB kinase. J. Biol. Chem. 274 (1999) 23061-23067
4. Maity A., McKenna W.G., and Muschel R.J. The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother. Oncol. 31 (1994) 1-13
5. Gius D., Botero A., Shah S., and Curry H.A. Intracellular oxidation/reduction status in the regulation of transcription factors NF-κB and AP-1. Toxicol. Lett. 106 (1999) 93-106
6. Abate C., Marshak D.R., and Curran T. Fos is phosphorylated by p34cdc2, cAMP-dependent protein kinase and protein kinase C at multiple sites clustered within regulatory regions. Oncogene 6 (1991) 2179-2185
7. Kerppola T.K., and Curran T. Zen and the art of Fos and Jun. Nature 373 (1995) 199-200
8. Gius D., Cao X.M., Rauscher III F.J., Cohen D.R., Curran T., and Sukhatme V.P. Transcriptional activation and repression by Fos are independent functions: the C terminus represses immediate-early gene expression via CArG elements. Mol. Cell. Biol. 10 (1990) 4243-4255
9. Spitz D.R., Sim J.E., Ridnour L.A., Galoforo S.S., and Lee Y.J. Glucose deprivation-induced oxidative stress in human tumor cells: a fundamental defect in metabolism?. Ann. NY Acad. Sci. 899 (2000) 349-362
10. Demple B., and Amabile-Cuevas C.F. Redox: the control of oxidative stress responses. Cell 67 (1991) 837-839
11. Storz G., Tartaglia L.A., Farr S.B., and Ames B.N. Bacterial defenses against oxidative stress. Trends Genet. 6 (1990) 363-368
12. Bisht K.S., Bradbury C.M., Mattson D., Kaushal A., Sowers A., Markovina S., et al. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res. 63 (2003) 8984-8995
13. Smart D.K., Ortiz K.L., Mattson D., Bradbury C.M., Bisht K.S., Sieck L.K., et al. Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Cancer Res. 64 (2004) 6716-6724
14. Spitz D.R., Kinter M.T., and Roberts R.J. Contribution of increased glutathione content to mechanisms of oxidative stress resistance in hydrogen peroxide resistant hamster fibroblasts. J. Cell. Physiol. 165 (1995) 600-609
15. Abate C., Luk D., and Curran T. Transcriptional regulation by Fos and Jun in vitro: interaction among multiple activator and regulatory domains. Mol. Cell. Biol. 11 (1991) 3624-3632
16. Halliwell B., and Gutteridge J.M. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 186 (1990) 1-85
17. Sun Y., and Oberley L.W. Redox regulation of transcriptional activators. Free Radic. Biol. Med. 21 (1996) 335-348
18. Datta R., Hallahan S.E., Kharbanda S.M., Rubin E., Sherman M.L., Huberman E., et al. Involvement of reactive oxygen intermediates in the induction of c-jun gene transcription by ionizing radiation. Biochemistry 31 (1992) 8300-8306
19. 2-resistant Chinese hamster fibroblasts. J. Cell. Physiol. 142 (1990) 255-260
20. 2 stimulate mitogen-activated protein kinase activity in NIH3T3 cells through the formation of reactive oxygen intermediates. Cancer Res. 54 (1994) 12-15
21. Diamond D.A., Parsian A., Hunt C.R., Lofgren S., Spitz D.R., Goswami P.C., and Gius D. Redox Factor-1 (Ref-1) mediates the activation of AP-1 in HeLa and NIH 3T3 cells in response to heat. J. Biol. Chem. 274 (1999) 16959-16964
22. Cullen K.J., Newkirk K.A., Schumaker L.M., Aldosari N., Rone J.D., and Haddad B.R. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res. 63 (2003) 8097-8102
23. Halliwell B., and Gutteridge J.M. Free radicals and antioxidant production: mechanisms and significance in toxicology and disease. Hum. Toxicol. 7 (1988) 7-13
24. Gius D., Botero A., Shah S., and Curry H.A. Intracellular oxidation/reduction status in the regulation of transcription factors NF-κB and AP-1. Toxicol. Lett. 106 (1999) 93-106
25. Abate C., Patel L., Rauscher III F.J., and Curran T. Redox regulation of Fos and Jun DNA-binding activity in vitro. Science 249 (1990) 1157-1161
26. Abate C., Marshak D.R., and Curran T. Fos is phosphorylated by p34cdc2, cAMP-dependent protein kinase and protein kinase C at multiple sites clustered within regulatory regions. Oncogene 6 (1991) 2179-2185
27. Kamada K., Goto S., Okunaga T., Ihara Y., Tsuji K., kawai Y., et al. Nuclear glutathione S-transferase pi prevents apoptosis by reducing the oxidative stress-induced formation of exocyclic DNA products. Free Radic. Biol. Med. 37 (2004) 1875-1884
28. Howie A.F., Forrester L.M., Glancey M.J., Schlager J.J., Powis G., Beckett G.J., et al. Glutathione S-transferase and glutathione peroxidase expression in normal and tumor human tissues. Carcinogenesis 11 (1990) 451-458
29. Mitchell J.B., and Russo A. The role of glutathione in IR and drug induced cytotoxicity. Br. J. Cancer 8 (1987) 96-104
30. Bergendi L., Benes L., Durackova Z., and Ferencik M. Chemistry, physiology and pathology of free radicals. Life Sci. 65 (1999) 1865-1874
31. Freeman B.A., and Crapo J.D. Biology of disease: free radicals and tissue injury. Lab. Invest. 47 (1982) 412-426
32. Warburg O. On the origin of cancer cells. Science 132 (1956) 309-314
33. Weber G. Enzymology of cancer cells (Part I). New Eng. J. Med. 296 (1977) 486-492
34. Weber G. Enzymology of cancer cells (Part II). New Eng. J. Med. 296 (1977) 541-551
35. Lehninger A.L. Biochemistry (1976), Worth Publishers, Inc., New York pp. 245-441, 467-471, 849-850
36. Blackburn R.V., Spitz D.R., Liu S., Galoforo S.S., Sim J.E., Ridnour L.A., et al. Metabolic oxidative stress activates signal transduction and gene expression during glucose deprivation in human tumor cells. Free Radic. Biol. Med. 26 (1999) 419-430
37. Gupta A., Lee J.K., Galoforo S.S., Berns C.M., Martinez A.A., Corry P.M., et al. Differential effect of glucose deprivation on MAPK activation in drug sensitive human breast carcinoma MCF-7 and multidrug resistant MCF-7/ADR cells. Mol. Cell. Biochem. 170 (1997) 23-30
38. Biaglow J.E., Clark E.P., Epp E.R., Morse-Guadio M., Varnes M.E., and Mitchell J.B. Nonprotein thiols and the radiation response of A549 human lung carcinoma cells. Int. J. Radiat. Biol. 44 (1983) 489-495
39. Berggren M., Gallegos A., Gasdaska J.R., Gasdaska P.Y., Warneke J., and Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res. 16 (1996) 3459-3466
40. Williams C.H., Arscott D.L., Müller S., Lennon B.W., Ludwig M.L., Wang P.F., et al. Thioredoxin reductase two modes of catalysis have evolved. Eur. J. Biochem. 267 (2000) 6110-6119
41. Oberley T.D., Verwiebe E., Zhong W., Kang S.W., and Rhee S.G. Localization of the thioredoxin system in normal rat kidney. Free Radic. Biol. Med. 30 (2001) 412-424
42. Kirkpatrick D.L., Kuperus M., Dowdeswell M., Potier N., Donald L.J., Kunkel M., et al. Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem. Pharmacol. 55 (1998) 987-994
43. Choi J.H., Kim T.N., Kim S., Baek S.H., Kim J.H., Lee S.R., and Kim J.R. Over-expression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res. 22 (2002) 3331-3335
44. Lincoln D.T., Ali Emadi E.M., Tonissen K.F., and Clarke F.M. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res. 23 (2003) 2425-2433
45. Mustacich D., and Powis G. Thioredoxin reductase. Biochem. J. 346 (2000) 1-8
46. Becker K., Gromer S., Schirmer R.H., and Müller S. Thioredoxin reductase as a pathophysiological factor and drug target. Eur. J. Biochem. 267 (2000) 6118-6125
47. Powis G., Kirkpatrick D.L., Angulo M., and Baker A. Thioredoxin redox control of cell growth and death and the effects of inhibitors. Chem. Biol. Interact. 112 (1998) 23-34
48. Poole L.B., Reynolds C.M., Wood Z.A., Karplus P.A., Ellis H.R., and Calzi M.L. AhpF and other NADH: peroxiredoxin oxidoreductases, homologues of low Mr thioredoxin reductase. Eur. J. Biochem. 267 (2000) 6126-6133
49. Hirota K., Matsui M., Murata M., Takashima Y., Cheng F.S., Itoh T., et al. Nucleoredoxin, glutaredoxin, and thioredoxin differentially regulate NF-κB, AP-1, and CREB activation in HEK293 cells. Biochem. Biophys. Res. Commun. 274 (2000) 177-182
50. Hirota K., Nakamura H., Arai T., Ishii H., Bai J., Itoh T., et al. Geranylgeranylacetone enhances expression of thioredoxin and suppresses ethanol-induced cytotoxicity in cultured hepatocytes. Biochem. Biophys. Res. Commun. 275 (2000) 825-830
51. Wei S.J., Botero A., Hirota K., Bradbury C.M., Markovina S., Laszlo A., et al. Thioredoxin nuclear translocation and interaction with redox factor-1 activates the activator protein-1 transcription factor in response to ionizing radiation. Cancer Res. 60 (2000) 6688-6695
52. Karimpour S., Lou J., Lin L.L., Rene L.M., Lagunas L., Ma R., et al. Thioredoxin reductase regulates AP-1 activity as well as thioredoxin nuclear localization via active cysteines in response to ionizing radiation. Oncogene 21 (2002) 6317-6327
53. Kerr L.D., Inoue J., and Verma I.M. Signal transduction: a nuclear target. Curr. Opin. Cell Biol. 4 (1992) 496-501
54. Holbrook N.J., and Fornace Jr. A.J. Response to adversity: molecular control of gene activation following genotoxic stress. New Biol. 3 (1991) 825-833
55. Hallahan D.E., Dunphy E., Virudachalam S., Sukhatme V.P., Kufe D.W., and Weichselbaum R.R. C-jun and Egr-1 participate in the DNA synthesis and cell survival in response to ionizing radiation exposure. J. Biol. Chem. 270 (1995) 30303-30309
56. Weichselbaum R.R., Hallahan D., Fuks Z., and Kufe D. Radiation induction of immediate early genes: effectors of the radiation-stress response. Int. J. Radiat. Oncol. Biol. Phys. 30 (1994) 229-234
57. Karin M., and Smeal T. Control of transcription factors by signal transduction pathways: the beginning of the end. Trends Biochem. Sci. 17 (1992) 418-422
58. Hallahan D.E., Gius D., Kuchibhotla J., Sukhatme V., Kufe D.W., and Weichselbaum R.R. Radiation signaling mediated by Jun activation following dissociation from a cell type-specific repressor. J. Biol. Chem. 268 (1993) 4903-4907
59. Xanthoudakis S., and Curran T. Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. Eur. Mol. Biol. Org. J. 11 (1992) 653-664
60. Xanthoudakis S., Miao G.G., Wang F., Pan Y.-C.E., and Curran T. Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. Eur. Mol. Biol. Org. J. 11 (1992) 3323-3335
61. Nakamura H., Bai J., Nishinaka Y., Ueda S., Sasada T., Ohshio G., et al. Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect. Prev. 24 (2000) 53-60
62. Powis G., Oblong J.E., Gasdaska P.Y., Berggren M., Hill S.R., and Kirkpatrick D.L. The thioredoxin/thioredoxin reductase redox system and control of cell growth. Oncol. Res. 6 (1994) 539-544
63. Nishinaka Y., Nakamura H., Masutani H., and Yodoi J. Redox control of cellular function by thioredoxin; a new therapeutic direction in host defence. Arch. Immunol. Ther. Exp. (Warsz) 49 (2001) 285-292
64. Nishinaka Y., Nishiyama A., Masutani H., Oka S., Ahsan K.M., Nakayama Y., et al. Loss of thioredoxin-binding protein-2/vitamin D3 up-regulated protein 1 in human T-cell leukemia virus type I-dependent T-cell transformation: implications for adult T-cell leukemia leukemogenesis. Cancer Res. 64 (2004) 1287-1292
65. Berggren M.I., Husbeck B., Samulitis B., Baker A.F., Gallegos A., and Powis G. Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not other agents including dexamethasone, etoposide, and doxorubicin. Arch. Biochem. Biophys. 392 (2001) 103-109
66. Wang G., Olczak A.A., Walton J.P., and Maier R.J. Contribution of the Helicobacter pylori thiol peroxidase bacterioferritin comigratory protein to oxidative stress resistance and host colonization. Infect. Immunol. 73 (2005) 378-384
67. Nonn L., Berggren M., and Powis G. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol. Cancer Res. 1 (2003) 682-689
68. Radyuk S.N., Sohal R.S., and Orr W.C. Thioredoxin peroxidases can foster cytoprotection or cell death in response to different stressors: over- and under-expression of thioredoxin peroxidase in Drosophila cells. Biochem. J. 371 (2003) 743-752
69. Depeille P., Cuq P., Mary S., Passagne I., Evrard A., Cupissol D., and Vian L. Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects. Mol. Pharmacol. 65 (2004) 897-905
70. Gladyshev V.N., Factor V.M., Housseau F., and Hatfield D.L. Contrasting patterns of regulation of the antioxidant slenoproteins, thioredoxin reductase, and glutathione peroxidase, in cancer cells. Biochem. Biophys. Res. Commun. 251 (1998) 488-493
71. Rundlof A.-K., and Arner E.S.J. Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events. Antioxid. Redox Signal. 6 (2004) 41-52
72. Welsh S.J., Bellamy W.T., Briehl M.M., and Powis G. The redox protein thioredoxin-1 (trx-1) increases hypoxia-inducible factor 1a protein expression: Trx-1 over-expression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. 62 (2002) 5089-5095
73. Kakolyris S., Giatromanolaki A., Koukourakis M., Powis G., Souglakos J., Sivridis E., et al. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin. Cancer Res. 7 (2001) 3087-3091
74. Raffel J., Bhattacharyya A.K., Gallegos A., Cui H., Einspahr J.G., Alberts D.S., and Powis G. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J. Lab. Clin. Med. 142 (2003) 46-51
75. Kim H.J., Chae H.Z., Kim Y.J., Kim Y.H., Hwang T.-S., Park E.-M., and Park Y.M. Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol. Toxicol. 19 (2003) 285-298
76. Han H., Bearss D.J., Browne L.W., Calaluce R., Nagle R.B., and Von Hoff D.D. Identification of differentially expressed genes in pancreatic cancer cells using cdna microarrays. Cancer Res. 62 (2002) 2890-2896
77. Hedley D., Pitilie M., Woo J., Nicklee T., Morrison A., Birle D., et al. Up-regulation of the redox mediators thioredoxin and apurinic/apyrimidinic excision (APE)/Ref-1 in hypoxic microregions of invasive cervical carcinomas, mapped using multispectral, wide-field fluorescence image analysis. Am. J. Pathol. 164 (2004) 557-565
78. Powis G., Briehl M., and Oblong J. Redox signaling and the control of cell growth and death. Pharmacol. Ther. 68 (1995) 149-173
79. Powis G., and Montfort W.R. Properties and biological activities of thioredoxins. Annu. Rev. Biophys. Biomol. Struct. 30 (2001) 421-455
80. Tuttle S.W., Varnes M.E., Mitchell J.B., and Biaglow J.E. Sensitivity to chemical oxidants and radiation in CHO cell lines deficient in oxidative pentose cycle activity. Int. J. Radiat. Oncol. Biol. Phys. 22 (1992) 671-675
81. Yao K.S., Xanthoudakis S., Curran T., and O'Dwyer P.J. Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia. Mol. Cell. Biol. 14 (1994) 5997-6003
82. Holmgren A. Thioredoxin and glutaredoxin systems. J. Biol. Chem. 264 (1989) 13963-13966
83. Ren X., Bjornstedt M., Shen B., Ericson M.L., and Holmgren A. Mutagenesis of structural half-cysteine residues in human thioredoxin and effects on the regulation of activity by selenodiglutathione. Biochemistry 32 (1993) 9701-9708
84. Sasada T., Sono H., and Yodoi J. Thioredoxin/adult T-cell leukemia-derived factor (ADF) and redox regulation. J. Toxicol. Sci. 21 (1996) 285-287
85. Engman L., Al-Maharik N., McNaughton M., Birmingham A., and Powis G. Thioredoxin reductase and cancer cell growth inhibition by organotellurium antioxidants. Anticancer Drugs 14 (2003) 153-161
86. Wipf P., Hopkins T.D., Jung J.K., Rodriguez S., Birmingham A., Southwick E.C., et al. New inhibitors of the thioredoxin-thioredoxin reductase system based on a naphthoquinone spiroketal natural product lead. Bioorg. Med. Chem. Lett. 11 (2001) 2637-2641
87. Xanthoudakis S., and Curran T. Redox regulation of AP-1: a link between transcription factor signaling and DNA repair. Adv. Exp. Med. Biol. 387 (1996) 69-75
88. Curry H.A., Clemens R.A., Shah S., Bradbury C.M., Botero A., Goswami P., and Gius D. Heat shock inhibits radiation-induced nuclear localization and activation of NF-κB DNA-binding. Possible role in radiation sensitization of tumor cells. J. Biol. Chem. 274 (1999) 23061-23067
89. Chen Z.J., Parent L., and Maniatis T. Site-specific phosphorylation of Iκ-Bα by a novel ubiquitination-dependent protein kinase activity. Cell 84 (1996) 853-862
90. Ang W.H., Khalaila I., Allardyce C.S., Juillerat-Jeanneret L., and Dyson P.J. Rational design of platinum (IV) compounds to overcome glutathione-S-transferase mediated drug resistance. J. Am. Chem. Soc. 127 (2005) 1382-1383
91. Du J., Pan Y., Shi Y., Guo C., Jin X., Sun L., et al. Over-expression and significance of prion protein in gastric cancer and multidrug-resistant gastric carcinoma cell line SGC7901/ADR. Int. J. Cancer. 113 (2005) 213-220